石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

未开盘 07-22 16:08:03

2.430

-0.030

-1.22%

最高2.470	最低2.400	成交量239.60万
今开2.440	昨收2.460	日振幅2.85%
总市值70.25亿	流通市值70.25亿	总股本28.91亿
成交额582.25万	换手率0.08%	流通股本28.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.43,"timestamp":1784707683004,"preClose":2.46,"halted":0,"volume":2396000,"delay":0,"changeRate":-0.012195121951219433,"floatShares":2891000000,"shares":2891000000,"eps":0.1605,"marketStatus":"未开盘","change":-0.03,"latestTime":"07-22 16:08:03","open":2.44,"high":2.47,"low":2.4,"amount":5822520,"amplitude":0.028455,"askPrice":2.43,"askSize":194000,"bidPrice":2.42,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.1605,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784770200000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.46,"dividendRate":0.032922,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":0.46909891190056896,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2653405932","title":"石四药集团：钆布醇获批登记为原料药 用于磁共振成像检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2653405932","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653405932?lang=zh_cn&edition=full","pubTime":"2026-07-21 09:56","pubTimestamp":1784598960,"startTime":"0","endTime":"0","summary":"7月21日，石四药集团（02005）发布公告，集团的钆布醇已获得中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。钆布醇是一种磁共振成像造影剂，适用于成人及全年龄段儿童（包括足月新生儿），主要用于全身各部位病变的对比增强磁共振成像（CE-MRI）检查，以及全身各部位的对比增强磁共振血管造影（CE-MRA）检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213814485445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653244865","title":"石四药集团(02005.HK)：钆布醇获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653244865","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653244865?lang=zh_cn&edition=full","pubTime":"2026-07-21 07:59","pubTimestamp":1784591982,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651415715","title":"港股异动 | 石四药集团(02005.HK)涨超4% 非诺贝特酸胆碱缓释胶囊取得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2651415715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651415715?lang=zh_cn&edition=full","pubTime":"2026-07-16 13:43","pubTimestamp":1784180609,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158981684","title":"石四药集团（02005）获批非诺贝特酸胆碱135mg缓释胶囊生产注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1158981684","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158981684?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:11","pubTimestamp":1784175117,"startTime":"0","endTime":"0","summary":"石四药集团有限公司7月16日公布，自愿公告显示，公司已取得中国国家药品监督管理局签发的非诺贝特酸胆碱缓释胶囊药品生产注册批件。该产品属于化学药品第4类，可视同通过一致性评价。公司指出，相较传统非诺贝特，非诺贝特酸胆碱具有直接起效、降低肝肾负担、服药不受进食限制，可与他汀类药物安全联合使用等临床优势。石四药集团称，本次获批标志着集团在高端降甘油三酯药物领域的产品迭代取得进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413889","title":"石四药集团(02005)：非诺贝特酸胆碱缓释胶囊(135mg)取得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413889","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651413889?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:11","pubTimestamp":1784175065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团已取得中国国家药品监督管理局有关非诺贝特酸胆碱缓释胶囊(135mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。非诺贝特酸胆碱缓释胶囊主要在成人控制饮食基础上，用于降低重度高甘油三酯血症患者的甘油三酯水平，以及用于原发性高胆固醇血症或混合型血脂异常患者的治疗。相较传统的非诺贝特，非诺贝特酸胆碱直接起效、肝肾负担更低、服药不受进食限制，且可安全搭配他汀类药品，是临床刚需的高端降甘油三酯换代产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：非诺贝特酸胆碱缓释胶囊(135mg)取得药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197810239","title":"石四药集团获批生产注册非诺贝特胆碱缓释胶囊（135毫克）","url":"https://stock-news.laohu8.com/highlight/detail?id=1197810239","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197810239?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:10","pubTimestamp":1784175017,"startTime":"0","endTime":"0","summary":"石四药集团宣布，其非诺贝特胆碱缓释胶囊（135毫克）已成功获得药品生产注册批准。这一进展标志着该药物在商业化道路上迈出了关键一步，为集团产品线增添了新的重要成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163247546","title":"石四药集团(02005)玛巴洛沙韦原料药获国家药监局批准 登记为上市制剂用API","url":"https://stock-news.laohu8.com/highlight/detail?id=1163247546","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163247546?lang=zh_cn&edition=full","pubTime":"2026-07-13 12:05","pubTimestamp":1783915531,"startTime":"0","endTime":"0","summary":"石四药集团有限公司（02005.HK）7月13日公告称，集团自主研发的玛巴洛沙韦原料药已获中国国家药品监督管理局批准登记，用于在上市制剂中的应用，公司成为国内第三家获批企业。\n公告显示，玛巴洛沙韦主要适用于甲型和乙型流感病毒治疗。公司表示，此次批准旨在向股东及潜在投资者披露最新业务进展。\n本次公告属于自愿信息披露，不涉及财务数据及盈利预测。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163847555","title":"石四药集团获批两款化学药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=1163847555","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163847555?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:36","pubTimestamp":1783672591,"startTime":"0","endTime":"0","summary":"2026年7月10日，石四药集团公告称，已获得中国国家药品监督管理局核发的两项化学药品生产注册批件。石四药集团指出，丙硫氧嘧啶片获批为化学药品第4类产品，视同通过一致性评价，为国内第三家取得该药品批件的企业。连同此前已获批的葡萄糖酸钙氯化钠注射液及葡萄糖酸钙注射液，公司已构建起完整的钙制剂产品系列。公司表示，本次公告属自愿披露，旨在向股东及潜在投资者说明最新业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650418323","title":"石四药集团(02005)已取得丙硫氧嘧啶片(50mg)、葡萄糖酸钙氯化钠注射液(50ml:1g/0.3375g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2650418323","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650418323?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:32","pubTimestamp":1783672374,"startTime":"0","endTime":"0","summary":"丙硫氧嘧啶片主要用于对甲巯咪唑不耐受的各种类型的甲状腺功能亢进症。此外，集团已取得国家药监局有关葡萄糖酸钙氯化钠注射液石四药集团已取得丙硫氧嘧啶片、葡萄糖酸钙氯化钠注射液的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。葡萄糖酸钙氯化钠注射液主要用于治疗急性低钙血症、镁中毒及氟中毒，并与集团已获批的葡萄糖酸钙氯化钠注射液、葡萄糖酸钙氯化钠注射液及葡萄糖酸钙注射液共同构建了钙制剂产品系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901368","title":"石四药集团(02005)：95个品种产品纳入国家基本药物目录(2026年版)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901368","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650901368?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:23","pubTimestamp":1783657381,"startTime":"0","endTime":"0","summary":"该目录将于2026年9月1日起实行，预期对集团的增长及业务发展带来正面影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185777354","title":"石四药集团获NMPA批准生产甲丙氨酯片剂(0.5克)","url":"https://stock-news.laohu8.com/highlight/detail?id=1185777354","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185777354?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:46","pubTimestamp":1783413970,"startTime":"0","endTime":"0","summary":"7月2日，石四药集团宣布，其甲丙氨酯片剂(0.5g)已获得中国国家药品监督管理局的上市批准。此外，公司亦取得了间苯三酚二水合物作为原料药的注册批件。这些进展标志着石四药集团在相关产品管线上的重要突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197595528","title":"石四药集团6月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1197595528","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197595528?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:35","pubTimestamp":1782984924,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年7月2日发布截至2026年6月30日的证券变动月报表。公告显示，6月期间公司已发行及注册股本均无变动，股本维持稳定。期间公司未进行股份购回和注销，公司声明已符合相关上市规则所规定的最低公眾持股量要求。本次公告由执行董事兼公司秘书周兴扬签署。公司表示，将持续遵守香港联合交易所有限公司《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648261522","title":"石四药集团(02005)：美索巴莫片(0.5g)获药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2648261522","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648261522?lang=zh_cn&edition=full","pubTime":"2026-07-02 07:56","pubTimestamp":1782950175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团是首家国内企业取得中国国家药品监督管理局(国家药监局)有关美索巴莫片(0.5g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。美索巴莫片是一种肌肉松弛药，主要用于关节肌肉扭伤、腰肌劳损、坐骨神经痛等病症。本集团的间苯三酚已获国家药监局批准登记成为在上市制剂使用的原料药。间苯三酚主要用于(i)消化系统和胆道功能障碍引起的急性痉挛疼痛;(ii)急性痉挛性尿道、膀胱、肾绞痛;及(iii)妇科痉挛性疼痛。诚如本公司日期为2024年8月27日的公告所载，本集团已取得国家药监局有关间苯三酚注射液的药品生产注册批件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：美索巴莫片(0.5g)获药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646911330","title":"石四药集团(02005.HK)：受托人根据限制性股份奖励计划购买60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646911330","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646911330?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:39","pubTimestamp":1782463193,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645789650","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645789650","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645789650?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:09","pubTimestamp":1782292156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年6月24日，由本公司内部资源拨付，计划受托人根据限制性股份奖励计划的条款及条件在公开市场上购买合共100万股本公司股份，并以信托方式为获选参与者(定义见计划)持有该等股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共100万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881112","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881112","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645881112?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:45","pubTimestamp":1782204300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年6月23日，由公司内部资源拨付，计划受托人根据计划之条款及条件在公开市场上购买合共200万股公司股份，并以信托方式为获选参与者持有该等股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645432310","title":"石四药集团：两款仿制药获批 帕金森、呼吸领域产品再添管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2645432310","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645432310?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:12","pubTimestamp":1782101520,"startTime":"0","endTime":"0","summary":"6月22日，石四药集团（02005）发布公告，本集团已取得中国国家药品监督管理局有关甲磺酸沙非胺片（100mg及50mg）的药品生产注册批件，属于化学药品第4类，视同通过一致性评价，是国内企业第三家获批。甲磺酸沙非胺片主要用于原发性帕金森病伴症状波动成人患者的联合治疗，与左旋多巴等其他帕金森病药物联合使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223777775330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743777","title":"石四药集团坐不住了？净利暴跌55％后两天签下六款新药，大输液龙头能否跑赢生死时速","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743777","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644743777?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:24","pubTimestamp":1781695490,"startTime":"0","endTime":"0","summary":"一则引进合作公告，与一份大幅下滑的财务报告，共同勾勒出这家传统输液龙头当下的真实处境。6月初，石四药集团（02005.HK）连续两天宣布引进六款产品，包括两款改良型新药和四款生物类似药，试图在主营业务持续承压的局面下加速转型。而就在三个月前，石四药集团交出的2025年成绩单显示：全年营业收入41.65亿港元，同比下滑27.8%，归母净利润4.71亿港元，同比骤降55.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606173774767180.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173774767180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714850","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714850","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714850?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:45","pubTimestamp":1781685911,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年6月17日，由本公司内部资源拨付，计划受托人根据于2018年12月27日采纳的限制性股份奖励计划的条款及条件在公开市场上购买合共38万股本公司股份，并以信托方式为获选参与者持有该等股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643078427","title":"石四药集团(02005)取得有关头孢泊肟酯干混悬剂(50mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2643078427","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643078427?lang=zh_cn&edition=full","pubTime":"2026-06-16 08:17","pubTimestamp":1781569057,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)公布，集团已取得中国国家药品监督管理局有关头孢泊肟酯干混悬剂(50mg)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。头孢泊肟酯干混悬剂主要用于治疗敏感菌引起的感染，包括上呼吸道感染、下呼吸道感染、单纯性泌尿道感染、单纯性皮肤和皮肤软组织感染、急性单纯性淋球菌性尿道炎和子宫颈炎，以及由奈瑟氏淋球菌引起的肛周炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得有关头孢泊肟酯干混悬剂(50mg)的药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":0.203},{"period":"3month","weight":0.0301},{"period":"6month","weight":-0.1796},{"period":"1year","weight":-0.198},{"period":"ytd","weight":-0.1303}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008158},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020535},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079315},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030939},{"month":5,"riseRate":0.47619,"avgChangeRate":0.010534},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060362},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.019444},{"month":8,"riseRate":0.35,"avgChangeRate":-0.017719},{"month":9,"riseRate":0.3,"avgChangeRate":-0.046842},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001891},{"month":11,"riseRate":0.65,"avgChangeRate":0.086083},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009107}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}